Interleukin-4 potential immunoregulatory agent in therapy of insulin-dependent diabetes mellitus

Clinical Immunotherapeutics

Volumn 6, Issue 4, 1996, Pages 251-260

  Arreaza, Guillermo A ^a   Cameron, Mark ^a   Delovitch, Terry L ^a  

^a ROBARTS RESEARCH INSTITUTE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 4; RECOMBINANT INTERLEUKIN 4;

AUTOIMMUNITY; DRUG THERAPY; ETIOLOGY; HELPER CELL; HUMAN; IMMUNOREGULATION; INSULIN DEPENDENT DIABETES MELLITUS; INTRAVENOUS DRUG ADMINISTRATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; REVIEW; T LYMPHOCYTE SUBPOPULATION;

EID: 0029785167     PISSN: 11727039     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF03259087     Document Type: Article

References (103)

1. Bach J. Insulin-dependent diabetes mellitus as an autoimmune disease. Endocrine Rev 1994; 15: 516-42
2. Bosi E, Botazzo GF. Autoimmunity in insulin-dependent diabetes mellitus. Clin Immunother 1995; 3: 125-35
3. Atkinson MA, Maclaren NK. Mechanisms of disease: the pathogenesis of insulin-dependent diabetes mellitus. N Engl JMed 1994;331: 1428-36
4. Ogawa M, Maruyama T, Hasegawa T, et al. The inhibitory effect of neonatal thymectomy on the incidence of insulitis in nonobese diabetic (NOD) mice. Biomed Res 1985; 6: 103-5
5. Bendelac A, Carnaud C, Boitard C, et al. Syngeneic transfer of autoimmune diabetes from NOD mice to healthy neonates. J ExpMed 1987; 166:823-32
6. Rohane PW, Shimada A, Kim DT, et al. Islet-infiltrating lymphocytes from prediabetic NOD mice rapidly transfer diabetes to NOD-scid/scid mice. Diabetes 1995; 44: 550-4
7. Christianson SW, Shultz LD, Leiter EH. Adoptive transfer of diabetes into immunodeficient NOD-scid/scid mice: relative contributions of CD4+ and CD8+ T cells from diabetic versus prediabetic NOD.NON-Thy-la donors. Diabetes 1993; 42: 44-55
8. Wang Y, Pontesilli O, Gill RG, et al. The role of CD4+ and CD8+ T cells in the destruction of islets grafts by spontaneously diabetic mice. Proc Natl Acad Sei USA 1991; 88: 527-31
9. Seder R, Paul WE. Acquisition of lymphokine-producing phenotype by CD4+ T cells. Annu Rev Immunol 1994; 12: 635-73
10. Paul WE, Seder RA. Lymphocyte responses and cytokines. Cell 1994; 76: 241-51
11. Romagnani S. Lymphokine production by human T cells in disease states. Annu Rev Immunol 1994; 12: 227-57
12. De Carli M, D'elios MM, Zancuoghi G, et al. Human TH1 and TH2 cells: functional properties, regulation of development and role in autoimmunity. Autoimmunity 1994; 18: 301-8
13. Ridgway WM, Weiner HL, Fathman CG. Regulation of autoimmune response. Curr Opin Immunol 1994; 6: 946-55
14. Liblau RS, Singer SM, McDevitt HO. TH1 and TH2 CD4+ T cells in the pathogenesis of organ-specific autoimmune diseases. Immunol Today 1995; 16: 34-8
15. Katz JD, Benoist C, Mathis D. T helper cell subsets in insulindependent diabetes. Science 1995; 268: 1185-8
16. Jaramillo A, Gill BM, Delovitch TL. Insulin-dependent diabetes mellitus in the non-obese diabetic mouse: a disease mediated by T cell anergy? Life Sei 1994; 55: 1163-77
17. Berman MA, Wang Z, Sandborg CI, et al. Deficiency in interleukin 4 (IL-4) production by T cells from new onset type 1 diabetes patients [abstract]. Diabetes 1995 May; 44 (Suppl. 1A-333): 137A
18. Rapoport MJ, Jaramillo A, Zipris D, et al. Interleukin 4 reverses T cell proliferative unresponsiveness and prevents the onset of diabetes in nonobese diabetic mice. J Exp Med 1993; 178: 87-99
19. Arreaza G, Cameron M, Chakrabarti S, et al. Effects of interleukin-4 administration and CD28 costimulation in thé pathogenesis of insulin dependent diabetes mellitus in the NOD mouse [abstract]. In: Keystone Symposia on Molecular and Cellular Biology; 1996 Mar 20-26: Hilton Head, South Carolina, USA: E4-4006
20. Rabinovitch A. Immunoregulatory and cytokine imbalances in the pathogenesis of IDDM. Diabetes 1994; 43: 613-21
21. Racke MK, Bonomo A, Scott DE, et al. Cytokine-induced immune deviation as a therapy for inflammatory autoimmune disease. J Exp Med 1994; 180: 1961-6
22. Rocken M, Shevach E. Immune deviation: the third dimension of nondeletional T cell tolerance. Immunol Rev 1996; 149: 175-94
23. Paul WE. Interleukin-4: a prototypic immunoregulatory lymphokine. Blood 1991; 77: 1859-70
24. Ricci M. IL-4: a key cytokine in atopy. Clin Exp Allergy 1994; 24: 801-12
25. Izuhara K, Yang G, Miyajima A, et al. Structure of the IL-4 receptor and signal transduction mechanism of IL-4. Res Immunol 1993; 144:584-90
26. Keegan AD, Nelms K, Wang L, et al. Interleukin 4 receptor: signaling mechanisms. Immunol Today 1994; 15: 423-32
27. Ivashkiv LB. Cytokines and STATs: how can signals achieve specificity? Immunity 1995; 3: 1-4
28. Quelle F, Shimoda K, Thierfelder W, et al. Cloning of murine Stat6 and human Stat6, Stat proteins that are tyrosine phosphorylated in responses to IL-4 and IL-13 but are not required for mitogenesis. Mol Cell Biol 1995; 15: 3336-43
29. Kaplan MH, Schindler U, Smiley ST, et al. Statô is required for mediating responses to IL-4 and for the development of TH2 cells. Immunity 1996; 4: 313-9
30. Aulitzky WE, Shuler M, Peschel C, et al. Interleukins: clinical pharmacology and therapeutic use. Drugs 1994; 48: 667-77
31. de Vries JE, Punnonen J, Cocks BG, et al. Regulation of Ihe human IgE response by IL-4 and IL-13. Res Immunol 1993; 144:597-601
32. de Waal Malefyt R, Figdor CG, de Vries JE. Effects of interleukin 4 on monocyte functions: comparison to interleukin 13. Res Immunol 1993; 144: 629-31
33. Zlotnick A, Godfrey DI, Fisher M, et al. Cytokine production by mature and immature CD4- CD8- T cells: a TCR+ CD4CD8-T cells produce IL-4. J Immunol 1992; 149: 1211-5
34. MacDonald HR. NK1.1+ T cell receptor-a+ cells: new clues to their origin, specificity and function. J Exp Med 1995; 182: 633-8
35. Arase H, Arase N, Nakagawa K, et al. NK1.1+ CD4+ CD8thymocytes with specific lymphokine secretion. Eur J Immunol 1993; 23: 307-10
36. Yoshimoto T, Paul WE. CD4+, NK1.1+ T cells promptly produce interleukin 4 in response to in vivo challenge with antiCD3. J Exp Med 1994; 179: 1285-95
37. Holter W. Regulation of IL-4 production and of IL-4 producing cells. Int Arch Allergy Immunol 1992; 98: 273-8
38. Kopf M, LegrosG, Bachmann M, et al. Disruption of the murine IL-4 gene blocks TH2 cytokine responses. Nature 1993; 326: 245-7
39. Tepper RI. The anti-tumour and proinflammatory actions of IL4. Res Immunol 1993; 144: 633-7
40. Obiri NI, Hillman GG, Haas GP, et al. Expression of high affinity interleukin-4 receptors on human renal cell carcinoma cells and inhibition of tumor cell growth in vitro by interleukin-4. J Clin Invest 1993; 91: 88-93
41. Kruuss JC, Strome SE, Chang AE, et al. Enhancement of immune reactivity in the lymph nodes draining a murine melanoma engineered to elaborate interleukin-4. J Immunother 1994; 16: 77-84
42. Miossec P. Chomarat P, Dechanet J. et al. IL-4 inhibits bone ré sorption through an effect on osteoclasts and pro-inflammatory eytokines in an ex vivo model of bone résorption in rheumatoid arthritis. Arthritis Rheum 1994; 37: 1715-22
43. Kunkel SL, Strieter RM. Lindley I, et al. Chemokines: new ligands, receptors and activities. Immunol Today 1995; 16: 559-61
44. Heinzel FP. Sadick MD. Holaday BJ, et al. Reciprocal expression of Interferon gamma or interleukin 4 during the resolution or progression of murine leishmaniasis: evidence lor expansion of distinct helper T cell subsets. J Exp Med 1989; 168: 59
45. Sadick MD, Heinzel FP, Holaday BJ, et al. Cure of murine leishmaniasis with anti-interleukin 4 monoclonal antibody: evidence for a T cell-dependent, Interferon gamma-independent mechanism. J Exp Med 1990: 171: 115
46. Heinzel FP. Schoenhaut DS, Rerko RM. et al. Recombinant interleukin 12 cures mice infected with Leishmaniu major. 1 Exp Med 1993: 177: 1505-9
47. Sypek JP, Chung CL, Mayor SEH, et al. Resolution of cutaneous leishmaniasis: interleukin 12 initiates a protective T helper type 1 immune response. J Exp Med 1993; 177: 1797-802
48. Wang Z, Reiner SL. Zheng S. et al. CD4+ effector cells default to the TH2 pathway in Interferon y-déficient mice infected with Leishmaniu major. J Exp Med 1994; 179: 1367-71
49. Salgame P, Ahrams JS, ClaybergerC.et al. Differing lymphokine profiles of functional subsets of human CD4 and CD8 T cell clones. Science 1991; 254: 279-82
50. Sieling PA, Abrams JS. Yamamura M. et al. Immunosuppressive roles for IL-10 and IL-4 in human infection. J Immunol 1993: 150:5501-10
51. Harrison LC, Honeyman MC, DeAizpurua HJ, et al. Inverse relation between humoral and cellular immunity to glutamic acid decarboxylase in subjects at risk of insulin-dependent diabetes. Lancet 1993; 341: 1365-9
52. Shehadeh NN, LaRosa F. Lafferty KJ. Altered cytokine activity in adjuvant inhibition of autoimmune diabetes. J Autoimmun 1993:291-300
53. Rabinovitch A. Sorcnsen O, Suarez-Pinzon WL, et ai. Analysis of cytokine mRNA expression in syngeneic islet grafts of NOD mice: interleukin 2 and interferon gamma mRNA expression correlate with graft rejection and interleukin 10 with graft survival. Diabetologia 1994: 37: 833-7
54. Suarez-Pinzon WL, Sorensen O. Guilbert LJ, et al. Analysis of cylokine-producing cells in syngeneic islet grafts in nonobese diabetic (NOD) mice: THI-type eytokines are correlative with islet -cell destruction and TH2-type eytokines with islet graft survival [abstract no. 6.8]. 5th International Congress on Pancreas and Islet Transplantation; 1995 Jun 18-22; Miami
55. Rabinovitch A, Suarez-Pinzon WL, Sorensen O. et al. Combined therapy with interleukin-4 and interleukin-10 inhibits autoimmune diabetes recurrence in syngeneie islet-transplanted nonobese diabetic mice. Transplantation 1995: 60: 368-74
56. Kennedy MK. Torrance DS, Picha KS, et al. Analysis of cytokine mRNA expression in the central nervous system of mice with experimental autoimmune encephalomyelitis reveals that 1L-10 mRNA expression correlates with recovery. J Immunol 1992; 149: 2496-505
57. Burlison EL. Drakes ML. Wood PJ. Differential patterns of production of granulocyte macrophage-colony stimulating factor, IL-2. IL-3 and IL-4 by cultured islets of Langerhans from non-obese diabetic and non-diabetic strains of mice. Int Immunol 1995: 7: 79-87
58. Fowell D. Mason D. Evidence that the T cell repertoire of normal rats contains cells with the potential to cause diabetes: characterization of the CD4+ T cell subset that inhibits this autoimmune potential. J Exp Med 1993: 177: 627-36
59. Katz J, Wang B, Haskins K, et al. Following a diabetogenic T cell from genesis through pathogenesis. Cell 1993; 74: 1089-100
60. Thompson CB. Distinct roles for the costimulatory ligands B7 I and B7-2 in T helper cell differentiation? Cell 1995: 81: 979-82
61. Bluestone JA. New perspectives of CD28-B7-mediated T cell costimulation. Immunity 1995: 2: 555-9
62. Kuchroo VK, Das MR Brown JA. et al. B7-I and B7-2 costimulatory molecules activate differentially the TH1/TH2 developmental pathways: application to autoimmune disease therapy. Cell 1995:80: 701-18
63. Freeman GJ. Buussiotis VA, Anumanthan A. et al. B7-I and B7-2 do not deliver identical costimulatory signals, since B72 but not B7-I preferentially costimulates the initial production of IL-4. Immunity 1995; 2: 523-32
64. KawamuraT, FurueM. Comparative analysis of B7-1 andB7-2 expression in Langerhans cells: differential regulation by T helper type 1 and T helper type 2 cytokines. Eur J Immunol 1995:25: 1913-7
65. Sayegh MH. Akalin E. Hancock WW, et al. CD28-B7 blockade after alloantigenic challenge in vivo inhibits TH1 cytokines but spares TH2. J Exp Med 1995: 181: 1869-74
66. King CL. Stupi RJ. Craighead N, et al. CD28 activation pro motes TH2 subset differentiation by human CD4+ cells. Eur J Immunol 1995:25: 587-95
67. Kaufman DL. Clare-Salzler M. Tian J. et al. Spontaneous loss of T cell tolerance to glutamic acid decarboxylase in murine insulin-dependent diabetes. Nature 1993: 366: 69-72
68. Tisch R, Yang X-D, Singer SM. el al. Immune response to glutamic acid decarboxylase correlates with insulitis in non-obese diabetic mice. Nature 1993: 366: 72-5
69. Ramiya V, Muir A. Maclaren N. Insulin prophylaxis in insulindependent diabetes mellitus: immunological rationale and therapeutic use. Clin Immunother 1995; 3: 177-83
70. Schloot N, Eisenbarth GS. Isohormonal therapy of endocrine autoimmunity. Immunol Today 1995; 16: 289-94
71. Weiner HL, Friedman A, Miller A, et al. Oral tolerance: immunologie mechanisms of treatment of animal and human organ-specific autoimmune diseases by oral administration of autoantigens. Annu Rev Immunol 1994; 12: 809-37
72. Gitimaraes V. Quintans J, Fisfalen ME, et al. Immunosuppression of thyroiditis [abstract]. Thyroid 1995; 5 Suppl. 1: S20
73. Wang T, Singh B. Warnock GL. et al. Prevention of recurrence of IDDM in islet-transplanted diabetic NOD mice by adjuvant immunotherapy. Diabetes 1992; 41: 114-7
74. Chatenoud L. Thervet E, Primo J. et al. Anli-CD3 antibody induces long-term remission of overt autoimmunity in nonobese diabetic mice. Proc Nail Acad Sei USA 1994; 91: 123-7
75. Pennline KJ. Roque-Gaffney E. Monahan M. Recombinant human 1L-10 prevents the onset of diabetes in the nonobese diabetic mouse. Clin Immunol Immunopathol 1994; 71: 169 75
76. Serreze DV. Hamaguchi K, Leiter EH. Immunostimulation circumvents diabetes in NOD/Lt mice. J Autoimmun 1989; 2: 759-76
77. Cash E. Minty A. Ferrara P. et al. Macrophage-inactivating IL13 suppresses experimental autoimmune encephalomyelilis in rats. J Immunol 1994: 153: 4258-67
78. Trembleau S, Germann T, Gately MK, et al. The role of IL-12 in the induction of organ-specific autoimmune diseases. Immunol Today 1995; 16: 383-6
79. Campbell IL, Oxbrow L, Koulmanda M, et al. IFN-y induces islet cell MHC antigens and enhances autoimmune streptozotocin-induced diabetes in the mouse. J Immunol 1988; 140: 1111-6
80. Debray-Sachs M, Carnaud C, Boitard C, et al. Prevention of diabetes in NOD mice treated with antibody to murine IFN-y. J Autoimmun 1991; 4: 237-48
81. Leonard JP, Waldburger KE, Goldman SJ. Prevention of experimental autoimmune encephalomyelitis by antibodies against interleukin 12. JExpMed 1995; 181:381-6
82. Wogensen L, Lee MS, Sarvetnick N. Production of interleukin 10 by islet cells accelerates immune-mediated destruction of cells in nonobese diabetic mice. J Exp Med 1994; 179: 1379-84
83. Sarvetnick N, Shizurus J, Liggit D, et al. Loss of pancreatic islet tolerance induced by beta cell expression of interferon gamma. Nature 1990; 346: 844-7
84. Mueller R, Krahl T, Sarvetnick N. Amelioration of diabetes by ectopic expression of interleukin-4 in NOD mice [abstract]. In: Keystone Symposia on Molecular and Cellular Biology; 1996 Mar 20-26: Hilton Head, South Carolina, USA: E4-4088
85. PerezVL, Lederer JA, Lichtman AH, et al. Stability of TH1 and TH2 populations. Int Immunol 1995; 7: 869-75
86. Szabo SJ, Jacobson NG, Dighe AS, et al. Developmental commitment to the TH2 lineage by extinction of IL-12 signaling. Immunity 1995; 2: 665-75
87. Murphy E, Shibuya K, Hosken N, et al. Reversibility of T helper 1 and 2 populations is lost after long-term stimulation. JExpMed 1996; 183:901-13
88. Plum J, De Smedt M, Leclercq G, et al. Inhibitory effect of murine recombinant IL-4 on thymocyte development in fetal thymus organ cultures. J Immunol 1990; 145: 1066-73
89. Gill BM, Delovitch TL. Elevated T cell PCD susceptibility may mediate onset of insulin-dependent diabetes mellitus [abstract]. In: 9th International Congress of Immunology; 1995. San Francisco: 4419
90. Standiford TJ, Kunkel SL, Liebler JM et al. Gene expression of macrophage inflammatory protein-1 alpha from human blood monocytes and alveolar macrophages is inhibited by interleukin 4. Am J RespirCell Mol Biol 1993; 9: 192-8
91. Sandler S, Sternesjö J. Interleukin 4 impairs rat pancreatic islet function in vitro by an action different to that of interleukin 1. Cytokine 1995; 7: 296-300
92. Clerici M, Shearer GM. The TH1-TH2 hypothesis of HIV infection: new insights. Immunol Today 1994; 15: 575-81
93. Anderson GP, Coyle AJ. TH1 - and TH2-like cells in allergy and asthma: pharmacological perspectives. Trends Pharmacol Sei 1994; 15: 324-32
94. Yoshimoto T, Bendelac A, Watson C, et al. Role of NK 1.1+ T cells in aTH2 response and in immunoglobulin E production. Science 1995:270: 1845-7
95. Schmidt-Wolf GD, Schmidt-Wolf IGH. Cytokines and gene therapy. Immunol Today 1995; 16: 173-5
96. Hunt JD, Pippin BA, Landreneau RJ, et al. Transfer and expression of the human interleukin-4 gene in carcinoma and stromal cell lines derived from lung cancer patients. J Immunother 1993; 14: 314-21
97. Chernajovsky Y, Feldmann M, Maini RN. Gene therapy of rheumatoid arthritis via cytokine regulation: future perspectives. BrMedBull 1995; 51: 503-16
98. Atkins MB, Vachino G, Tilg HJ, et al. Phase I evaluation of thrice-daily intravenous bolus interleukin-4 in patients with refractory malignancy. J Clin Oncol 1992; 10: 1802-9
99. Gilleece MH, Scarffe JH, Ghosh A, et al. Recombinant human interleukin 4 (IL-4) given as daily subcutaneous injections: a phase 1 dose toxicity trial. Br J Cancer 1992; 66: 204-10
100. Sosman J, Fisher S, Kefer C, et al. A phase I trial of continuous infusion interleukin-4 (IL-4) alone and following interleukin2 (1L-2) in cancer patients. Ann Oncol 1994; 5: 447-52
101. Margolin K, Aronson FR, Sznol M, et al. Phase II studies of recombinant human interleukin-4 in advanced renal cancer and malignant melanoma. J Immunother 1994; 15: 147-53
102. Trehu E, Isner J, Mier J, et al. Possible myocardial toxicity associated with interleukin-4 therapy. J Immunother 1993; 14: 348-51
103. Yoshimoto K, Swain SL, Bradley LM. Enhanced development of TH2-like CD4 effectors in response to sustained exposure to limited rIL-4 in vivo. J Immunol 1996; 156: 3267-74